Background: Cardiovascular (CV) disease is a major cause of morbidity in patients with type 2 diabetes mellitus (DM2). DM2 patients often experience Atrial Fibrillation (AF) with aggravated CV morbidity and mortality. We investigated the clinical risk factors in patients with DM2 hospitalized with AF with rapid ventricular response (RVR).
Methods: A retrospective study was conducted using a community hospital EMR database from 2013-2018. Adults with admission codes for AF with RVR were included in the study, and were stratified based on the presence or absence of DM2. Patient characteristics, and clinical outcomes were compared.
Results: Among 1643 patients with AF with RVR, 501 (30.5%) had DM2. Median (IQR) age for DM2 patients compared to controls was 72(64, 79) vs. 73(62, 83), P=0.12, 54.5% vs. 54.6% were female P=0.98, had coronary artery disease [39.5% vs. 25.3% (P<.0001)], heart failure (HF) [68.5% vs. 51.8 % (P<.0001)], hypertension [88% vs. 67.7% (P< 0.0001)]. length of stay (LOS), 3(2,6) days vs. 2(1,4) days, (P<.0001)] LOS was higher for DM2 patients with HF with 4(2,6) vs. 3(2,5) (p <.0001).
Conclusion: Among patients hospitalized for AF with RVR, DM2 patients had a higher prevalence of cardiovascular disease and longer LOS. A higher prevalence of HF may be a contributing factor to longer LOS. Understanding the risk of HF in patients with DM2 and AF is needed to address clinical outcomes in the future.
A. Alkhayru: None. B. Tappuni: None. B. Kaseer: None. D.M. Brandt: None. F. Ghazi: Speaker’s Bureau; Self; AstraZeneca K.K., Boston Scientific, Janssen Pharmaceuticals, Inc. M.W. Winner: None. K. Shemisa: Speaker’s Bureau; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Pfizer Inc.